PMN
ProMIS Neurosciences Inc.
NASDAQ: PMN · HEALTHCARE · BIOTECHNOLOGY
$10.49
-6.17% today
Updated 2026-06-05
Market cap
$91.02M
P/E ratio
—
P/S ratio
4,016.22x
EPS (TTM)
$-18.60
Dividend yield
—
52W range
$6 – $40
Volume
0.0M
ProMIS Neurosciences Inc. (PMN) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $4.76M | $12.77M | $9.71M | $4.37M | $5.31M | $1097.00 | $321808.00 | $316288.00 | $294543.00 | $1.15M | $967823.00 | $2.17M | $2.97M | $2.07M | $1.38M | $22.44M | $12.60M | $13.62M | $18.91M | $9.18M |
| Cash & equivalents | $97610.00 | $1.44M | $2.15M | $447111.00 | $234408.00 | $815.00 | $36256.00 | $35634.00 | $25008.00 | $903212.00 | $712042.00 | $1.69M | $2.39M | $1.66M | $1.03M | $21.43M | $10.69M | $12.60M | $13.29M | $6.12M |
| Current assets | $12.57M | $10.98M | $4.99M | $4.99M | $3.09M | $1019.00 | $210041.00 | $206438.00 | $205989.00 | $1.07M | $667827.00 | $1.68M | $2.91M | $2.03M | $1.24M | $22.40M | $12.56M | $13.62M | $18.91M | $9.18M |
| Total liabilities | $212624.00 | $575140.00 | $1.26M | $472011.00 | $634389.00 | $400.00 | $538056.00 | $528827.00 | $492775.00 | $550759.00 | $898390.00 | $637450.00 | $1.81M | $1.68M | $2.40M | $15.28M | $15.05M | $9.87M | $2.42M | $10.44M |
| Current liabilities | $212624.00 | $575140.00 | $596119.00 | $472011.00 | $634389.00 | $400.00 | $538056.00 | $528827.00 | $492775.00 | $550759.00 | $898390.00 | $637450.00 | $1.81M | $1.68M | $2.40M | $1.17M | $11.67M | $9.35M | $2.22M | $10.41M |
| Long-term debt | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $3.88M | — | — | — | — |
| Shareholder equity | $12.20M | $8.64M | $8.45M | $4.67M | $2.39M | $810933.00 | $-216248.00 | $-212539.00 | $-198232.00 | $599979.00 | $69433.00 | $1.53M | $1.16M | $398121.00 | $-1.02M | $7.16M | $-2.45M | $3.75M | $16.49M | $-1.26M |
| Retained earnings | $-5.52M | $-13.42M | $-14.86M | $-23.31M | $-27.16M | $-29.87M | $-32.03M | $-31.48M | $-36.43M | $-38.55M | $-42.00M | $-48.02M | $-58.19M | $-65.59M | $-71.25M | $-78.64M | $-146.00M | $-93.47M | $-90.69M | $-130.41M |
| Accounts receivable | $444884.00 | $466316.00 | $573737.00 | $546478.00 | $161619.00 | $151148.00 | $3669.00 | $182754.00 | $646.00 | $9157.00 | $6923.00 | $2168.00 | $1162.00 | $2510.00 | $756.00 | $48690.00 | $71626.00 | $78637.00 | $78034.00 | $36522.00 |
| Inventory | $0.00 | $0.00 | — | $1.00 | $0.00 | — | $0.00 | $1.00 | — | $-53485.00 | $-34435.00 | $-36690.00 | $-40135.00 | $-56819.00 | $-31044.00 | $-48690.00 | $-71626.00 | — | — | — |
| Goodwill | — | — | — | — | — | — | — | $-1600.00 | $-8261.00 | $-20947.00 | $-17487.00 | $-12621.00 | $-14609.00 | $-11322.00 | $-8980.00 | — | — | — | — | — |
Frequently asked questions
What is ProMIS Neurosciences Inc.'s revenue?
ProMIS Neurosciences Inc.'s trailing twelve-month revenue is $7560.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How much free cash flow does PMN generate?
PMN produced $-28.12M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is PMN's balance sheet healthy?
PMN holds $6.12M in cash and equivalents against — in long-term debt, on $-1.26M of shareholder equity. That debt is best read against the cash flow the business throws off each year.